Gilead, WHO Renew Visceral Leishmaniasis Partnership
Analysis based on 7 articles · First reported May 21, 2026 · Last updated May 21, 2026
The renewed partnership between Gilead Sciences and the World Health Organization is expected to have a positive impact on Gilead Sciences' reputation and ESG standing, potentially attracting socially conscious investors. The continued efforts to eliminate visceral leishmaniasis in high-burden countries could also open up new markets for related diagnostic and treatment solutions in the long term, although the direct financial impact on Gilead Sciences' stock price is likely to be minor given the philanthropic nature of the donations.
Gilead Sciences and the World Health Organization have renewed their five-year collaboration to accelerate the elimination of visceral leishmaniasis (VL), also known as kala-azar. This expanded agreement, running through 2030, includes Gilead Sciences' commitment to donate over 400,000 vials of Amphotericin B (amphotericin B) liposome for injection and provide $9.2 million in financial support. The partnership aims to improve access to life-saving diagnostic services and treatment, with a sharpened focus on high-burden countries in East Africa, including Ethiopia, Eritrea, Kenya, Somalia, South Sudan, Sudan, Uganda, Chad, and Djibouti, as well as Bangladesh, India, Nepal, and Yemen. The collaboration has already achieved significant progress, notably reducing new VL cases by over 95% in Southeast Asia since 2005 and leading to the World Health Organization's validation of Bangladesh's elimination of VL as a public health problem in 2023. Daniel O Day, CEO of Gilead Sciences, and Dr Jeremy Farrar, Assistant Director-General of the World Health Organization, both emphasized the importance of sustained commitment and strategic partnerships in reaching the goal of VL elimination.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard